1. A method of treating a chronic inflammatory disease, comprising: providing a drug composition comprising at least one of: θ-defensin, an analogue of θ-defensin or a derivative of θ-defensin, said drug composition being prepared to provide an anti-inflammatory effect； the introduction of the specified medicinal composition for the treatment of a chronic inflammatory condition. 2. The method of claim 1, wherein said drug composition is RTD-1-27, RTD-1-28, or RTD-1-29.3. A method according to claim 1, characterized in that the administration of the drug composition includes oral administration of the drug composition in doses effective to provide anti-inflammatory effects in the animal. A method according to claim 1, characterized in that said drug composition causes clinically significant inhibition of a pro-inflammatory protease. A method according to claim 4, characterized in that the pro-inflammatory protease is an enzyme that converts tumor necrosis factor alpha (TNFα) (TACE) .6. The method according to claim 1, characterized in that the anti-inflammatory effect includes clinically significant inhibition of sheddase or cathepsin C.7. A method according to claim 1, characterized in that the step of providing the drug composition comprises producing for sale at least one kilogram of said drug composition. The method of claim 1, wherein the step of providing the drug composition comprises packaging said drug composition in an oral dosage form. The method according to claim 1, characterized in that said inflammatory condition is1. Способ лечения хронического воспалительного заболевания, включающий:обеспечение лекарственной композиции, содержащей по меньшей мере одно из: θ-дефензина, аналога θ-дефензина или производного θ-дефензина, причем указанная лекарственная композиция приготовлена для обеспечения противовоспалительного действия； ивведение указанной лекарственной композиции для лечения хронического воспалительного состояния.2. Способ по п. 1, отличающийся тем,
